PubAg

Main content area

Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study B Analytical technologies in the biomedical and life sciences

Author:
Nardotto, Glauco Henrique Balthazar, Coelho, Eduardo Barbosa, Marques, Maria Paula, Lanchote, Vera Lucia
Source:
Journal of chromatography 2016 v.1015-1016 pp. 173-180
ISSN:
1570-0232
Subject:
aerobiosis, antagonists, antihypertensive agents, enantiomers, humans, hydroxyl radicals, liquid chromatography, metabolites, noninsulin-dependent diabetes mellitus, patients, pharmacokinetics, tandem mass spectrometry
Abstract:
Carvedilol is an antihypertensive drug, which is available in clinical practice as a racemic mixture. (S)-(−)-carvedilol is a β- and α1-adrenergic antagonist, while (R)-(+)-carvedilol only acts as an α1-adrenergic antagonist. Carvedilol is metabolized mainly by glucuronidation and, to a lesser extent, by CYP2D6 to hydroxyphenyl carvedilol (OHC) and by CYP2C9 to O-desmethyl carvedilol (DMC). This study describes the development and validation of a method for the sequential analysis of the enantiomers of carvedilol, OHC and DMC in plasma using a Chirobiotic® V chiral-phase column coupled to an LC–MS/MS system. The method was linear in the range of 0.05–100, 0.05–10 and 0.02–10ng/mL for the carvedilol, OHC and DMC enantiomers, respectively. Application of the method to the investigation of a patient with type 2 diabetes mellitus treated with a single oral dose of 25mg racemic carvedilol showed plasma accumulation of the (R)-(+)-carvedilol, (R)-(+)-DMC and (R)-(+)-OHC enantiomers. These results suggest that plasma accumulation of (R)-(+)-carvedilol cannot be explained by its oxidative metabolism.
Agid:
5306093